@article{oai:niigata-u.repo.nii.ac.jp:00021634,
 author = {帯刀, 亘},
 issue = {2},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Feb},
 note = {Heparin has long been used for disseminated intravascular coagulation (DIC), but recently some new drugs have become available for DIC. The concentrate of Antithrombin III, which is a physiological protease inhibitor, is used in combination with heparin. Low molecular weight heparin (LMWH) with molecular weight of about 4000～6000 has more anti-X_a activity than anti-IIa activity. For this reason, LMWH has an anticoagulant activity with a low bleeding risk. Synthetic protease inhibitors (eg. FUTHAN) directly inhibit several protease activities in the absence of antithrombin III. Activated protein C inactivates V_a and VIII_a with protein S as a cofactor, and inhibits plasminogen activator inhibitor. Its concentrate may be effective for patients with DIC especially caused by endotoxicemia. DIC is heterogeneous in coagulation-fibrinolysis balance and is associated with various diseases, so we must choose suitable drugs for individual patients.},
 pages = {103--108},
 title = {5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)},
 volume = {105},
 year = {1991}
}